Childhood Cancer Survivorship Clinic Addresses Unique Needs of Pediatric Cancer Survivors

Highlighting the importance of a multidisciplinary approach to care

22-CHP-3146209 CQD-Rotz-GenChildCancerSurvivalandObesity650x450

On their path to recovery, pediatric cancer survivors face unique health challenges that require care from a multidisciplinary team of providers with expertise in survivorship.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In a recent Q&A with Seth Rotz, MD, pediatric hematologist/oncologist and Director of the Cleveland Clinic Childhood Cancer Survivorship Clinic, he discusses the main goals of the center, which include a focus on long-term follow-up care of pediatric cancer survivors and the delivery of integrated multidisciplinary care.

Please give us some background on the Cleveland Clinic Childhood Cancer Survivorship Clinic. When was the program initiated, and what are its goals?

The clinic really took off in 2017, and the goal of the program is to provide comprehensive care to survivors of pediatric or young adult cancers and to make sure that we’re doing everything in our power to keep them healthy and living long lives. We do that by having conversations with the patients about the treatments that they received and the experience that they went through to identify any specific medical needs that they may have as a result of their treatment. This includes any unique risk factors they may have due to chemotherapy, radiation, or surgery, as well as the need to screen for long-term effects or to provide interventions.

How many patients does the clinic serve, and how long are they typically followed?

The clinic currently serves almost 300 patients. Most of them were treated at Cleveland Clinic or Northeast Ohio, but we also have some people that come to us from throughout the country.

There is no “aging out” of our clinic; I will follow people lifelong until I retire, or whatever the case may be. Right now, we have a lot of kids and young adults in their 20s and 30s in our clinic, but we also have people in their 40s, 50s and 60s.

What are some of the unique healthcare needs of this patient population?

Compared to other individuals of similar age, childhood cancer survivors have a much greater risk of developing chronic health conditions that can be limiting, disabling, or even increase the risk of early death. A lot of those issues stem from the treatments that they received.


Out in the community, most primary care providers don’t have the bandwidth to deal with the intricacies of different treatment regimens to be able to adequately counsel people on the risks and screen for health issues. That is where we come in ― not to do primary care, but to be specialists in survivorships and to make sure that people are getting the information they need to empower them to make healthy choices, as well as set up plans for different types of screening such as for secondary cancers or heart disease.

Tell us about the multidisciplinary approach to care offered to survivors in this program.

These patients are really unique—any two childhood cancer survivors will have gotten totally different treatment regimens and will be at totally different risks for long-term effects. Here at Cleveland Clinic, we are fortunate to have great colleagues on both the adult and pediatric sides. We also have colleagues in other disciplines who have interests in childhood cancer survivorship.

For example, if somebody is developing heart disease from their cancer chemotherapy, we have a pediatric cardiologist and an adult cardiologist we can refer them to, depending on how old they are at the time. We also work with male and female fertility experts, pulmonologists, and other specialists with whom we can engage to help us deliver customized care.

How important is it to not only address the physical symptoms but also take care of the emotional needs that may be unique to this patient population?

There’s a large amount of post-traumatic stress among childhood cancer survivors, and perhaps more so in older kids. Those kids who may have been younger [during treatment] may not remember things, but teenagers certainly do.

There are a lot of emotional demands on the patients that are associated with cancer treatment, as well as on parents, family members, and other caregivers who have gone through the process. So, we try to screen our survivors and people who are with them for those issues and connect them with mental health resources and support groups in the community.


What are currently considered “hot topics” in survivorship research?

I think that the directions we are moving in include a couple of things: one is figuring out what the underlying mechanisms are, and two is taking a look at some of the genetic susceptibilities — for example, why do we give two different patients high-dose anthracycline chemotherapy and one of them gets heart failure and the other doesn’t? Is there a genetic or lifestyle role in that? And lastly, interventions. What can we do, for example, to intervene and decrease the risk of heart disease?

Can you comment on the findings from a recent paper published in Nature on the link between the genetic risk score and severe obesity in childhood cancer survivors?

We do know that obesity, heart disease and diabetes are more prevalent in childhood cancer survivors, but this study took things one step further and looked at the genetic susceptibilities of obesity in childhood cancer patients to see if there are certain things that can further a patient’s risk of obesity and who can we target for aggressive interventions. So, going beyond just the clinical and demographic exposures and adding that genetic component.

How can survivorship research improve future treatments?

Through the work that’s been done previously, we have been able to more clearly understand what drugs and what types of radiation cause long-term problems. Oftentimes in pediatric oncology, we are taking a standard regimen and adding a new drug to that regimen to see if we can make the outcomes better. But we also have some diseases where the outcomes are already very good, and in those diseases, we focus on therapy reduction trials.

We are asking if we can start taking out some of the most toxic chemotherapies that are most likely to cause problems to the survivors and still have the same excellent outcomes, or whether we can reduce the doses of radiation—or reduce radiation altogether—and still have really good outcomes, or if we can reduce chemotherapy that is associated with infertility or heart disease, etc. Needless to say, survivorship data are critical and certainly inform the design of future clinical trials.

Related Articles

Little boy with cancer sitting in chair
April 11, 2024/Pediatrics
Outcomes in Hodgkin Lymphoma Are Improving, but Disparities Persist

Unpacking advancements and identifying drivers of inequity

Patient in hospital getting bone marrow transplant
Updated Recommendations for Long-Term Survivors of Bone Marrow Transplant

New guidelines expand on psychosocial, sexual health, cognitive and other issues

Closeup of bone marrow
Bridging the Gap Between Bone Marrow Transplant and cGvHD

Consensus conference begins work on new recommendations for clinical care and research

Smiling child in green shirt with superimposed outline of the lymphatic system
Trials to Study Use of 2 Cancer Drugs in Patients With Lymphatic Malformations

Genetic changes are similar between some vascular anomalies and cancers

Sickle Cell Disease: Transitioning Patients From Pediatric to Adult Care

How to combat the rise in mortality when patients become adults

Trial of Gene Therapy to Treat Sickle Cell Disease Reports Initial Positive Results

First in-human trial using CRISPR/CASP 12 for gene editing in sickle cell disease

23-CHP-3826419 CQD Thomas And Kodish – Ethicists Role
Paving a Pathway for Ethics in Pediatric Hematology/Oncology

A closer look at training, scholarship and opportunity within this sub subspecialty

22-CHP-3220861 CQD-Trucco – Phase 1 trial Disulfiram Combined
Trial Tests Alcoholism Drug in Relapsed/Refractory Sarcomas to Overcome Chemotherapy Resistance

Can disulfiram boost the efficacy of chemotherapy in this patient population?